If You Invested $100 In Vertex Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today

Morgan Stanley Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $612

Morgan Stanley analyst Terence Flynn maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $596 to $612.

The FDA Approves Expanded Use Of Vertex Pharmaceuticals' ALYFTREK (vanzacaftor/tezacaftor/ivacaftor) For Cystic Fibrosis In Patients 6 And Older

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people

Vertex Pharmaceuticals Submits Povetacicept For The Treatment Of Immunoglobulin A Nephropathy For Accelerated Approval From The FDA; Expects FDA Review To Be Accelerated From Usual 10-Month R

If You Invested $1000 In Vertex Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today

Watching Vertex Pharmaceuticals; Shares Trading Lower, FDA Label Update For ALYFTREK Adds Neuropsychiatric Risk Warning And Intracranial Hypertension, Alongside Strengthened Liver Safety Moni

https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218730s003lbl.pdf